Chordate Medical Holding AB (publ)
Stockholm Stock ExchangeTotal Valuation
Chordate Medical Holding AB (publ) carries a market capitalization of 269,962.00, placing it among publicly traded companies globally. Its enterprise value stands at 7.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 269,962.00 |
| Enterprise Value | 7.84M |
Share Statistics
Chordate Medical Holding AB (publ) currently has 2.70M shares outstanding.
| Shares Outstanding | 2.70M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12.17, and the price-to-book ratio stands at 0.70.
| PE Ratio | N/A |
| PS Ratio | 12.17 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | -0.51 |
| P/OCF Ratio | -0.49 |
Enterprise Valuation
| EV / Sales | 7.90 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Chordate Medical Holding AB (publ) maintains a current ratio of 1.97, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.97 |
| Quick Ratio | 1.02 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,736.97 |
Financial Efficiency
| Return on Equity (ROE) | -186.89 |
| Return on Assets (ROA) | -112.58 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.10 |
Stock Price Statistics
Chordate Medical Holding AB (publ)'s stock has declined approximately -98.23944% over the past 52 weeks. The 50-day moving average sits at 0.65, while the 200-day moving average is 4.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -98.23944% |
| 50-Day Moving Average | 0.65 |
| 200-Day Moving Average | 4.04 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chordate Medical Holding AB (publ) generated 993,329.00 in revenue and converted that into -25.16M in net income, yielding earnings per share of -14.70. EBITDA reached -25.21M, while operating income came in at -25.21M.
| Revenue | 993,329.00 |
| Gross Profit | 807,950.00 |
| Operating Income | -25.21M |
| Pretax Income | -25.16M |
| Net Income | -25.16M |
| EBITDA | -25.21M |
| EBIT | -25.21M |
| Earnings Per Share (EPS) | -14.70 |
Balance Sheet
Total book value stands at 17.16M, with working capital of 4.02M providing operational flexibility.
| Cash & Cash Equivalents | 4.24M |
| Total Debt | N/A |
| Net Debt | -4.24M |
| Equity (Book Value) | 17.16M |
| Book Value Per Share | 10.03 |
| Working Capital | 4.02M |
Cash Flow
Chordate Medical Holding AB (publ) produced -24.69M in operating cash flow over the past twelve months. After subtracting -1.08M in capital expenditures, free cash flow totaled -25.77M - equivalent to -15.05 per share.
| Operating Cash Flow | -24.69M |
| Capital Expenditures | -1.08M |
| Free Cash Flow | -25.77M |
| FCF Per Share | -15.05 |
Margins
Chordate Medical Holding AB (publ) operates with a gross margin of 81.34, reflecting its pricing power and cost economics. The operating margin of -2,538.32 and net profit margin of -2,532.89 provide insight into operational efficiency.
| Gross Margin | 81.34 |
| Operating Margin | -2,538.32 |
| Pretax Margin | -2,532.89 |
| Profit Margin | -2,532.89 |
| EBITDA Margin | -2,538.32 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -152.33 |
| FCF Yield | -195.30 |
Stock Splits
Chordate Medical Holding AB (publ)'s most recent stock split took place on August 29, 2024 with a 500:1 split ratio.
| Last Split Date | 8/29/2024 |
| Split Ratio | 500:1 |
Scores
Chordate Medical Holding AB (publ) posts an Altman Z-Score of -5.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.54 |